Clinical trials: Cancer of the Thyroid
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Thyroid Cancer
Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model
This study aims to refine the molecular classification of thyroid cancer (TC) using a multi-omics approach. By identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and…
- Trial name
- NCT06969768
- Where
- South Korea
- Volunteers
- 275 people
- Sponsor
- Seoul National University Hospital
Thyroid Cancer
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Study rationale High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation.
- Trial name
- NCT03841617
- Testing
- Thyrogen, I-131, I-124
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Head and Neck Neoplasms
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.
- Trial name
- NCT01057589
- Testing
- Pemetrexed, Cetuximab, Cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Papillary Thyroid Carcinoma
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.
To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V of Bethesda System)
- Trial name
- NCT02323724
- Testing
- BRAF V600E mutation by pyrosequencing technique
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Corporacion Parc Tauli
Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124.
- Trial name
- NCT03647358
- Testing
- PET/CT Scan, Iodine-124
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
The purpose of this study is to determine the effectiveness of two anticancer drugs, everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer responding to treatment with radioiodine or where it is…
- Trial name
- NCT01270321
- Testing
- Everolimus, Pasireotide, Everolimus and Pasireotide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Papillary Thyroid Carcinoma
Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma
Immunohistochemical detection of the BRAF-V600E mutation on pre-operative fine needle aspiration biopsy (FNAB) from patients suspected for papillary thyroid carcinoma, using the mutation specific antibody VE1.
- Trial name
- NCT02561533
- Testing
- BRAF detection on fine needle aspiration biopsy (FNAB)
- Where
- Denmark
- Volunteers
- 53 people
- Sponsor
- University of Aarhus
Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function
Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules
The purpose of this study is to compare treatment of hyperthyroidism with radiofrequency ablation or I-131 for solitary autonomous thyroid nodules.
- Conditions
- Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism, Radiofrequency Ablation
- Trial name
- RABITO (NCT05142904)
- Testing
- Radiofrequency ablation, Radioactive iodine
- Where
- 14 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Rijnstate Hospital
Thyroid, Thyroid Nodule
Comparison of TOETVA and Conventional Thyroidectomy
Introduction-Objective: The application of transoral endoscopic thyroidectomy vestibular approach (TOETVA) is gradually increasing recently.
- Conditions
- Thyroid, Thyroid Nodule, Surgery
- Trial name
- TOETVA (NCT04647006)
- Testing
- thyroid
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- MUnlu
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT02592356
- Testing
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer
Thyroid Cancer and (FDG)PET/CT Scan
Background and Rational (Introduction) Differentiated thyroid carcinoma (DTC) have favorable prognosis. Overall 10-year survival is 93% for papillary carcinoma, and 85% for follicular carcinoma(1).
- Trial name
- NCT04128631
- Volunteers
- 35 people
- Sponsor
- Assiut University
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma
- Trial name
- NCT00729157
- Testing
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Postoperative Hypoparathyroidism, Thyroid Neoplasms
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.
This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)'…
- Conditions
- Postoperative Hypoparathyroidism, Thyroid Neoplasms, Thyroid Cancer
- Trial name
- NIRAF (NCT04281875)
- Testing
- NIRAF Detection Technology
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Thyroid Neoplasms
Comparative Study in Oral, Breast Approach and Open Thyroidectomy
Purpose: Total endoscopic thyroidectomy including oral approach and breast approach has excellent cosmetic and several functional results.
- Trial name
- NCT03479801
- Testing
- Thyroid Surgical Methods
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Carcinoma
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof.
- Trial name
- NCT07138716
- Testing
- 68Ga-DOTA-CCK-FS PET/CT
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Luo Yaping
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.